Clinical-stage monoclonal antibodies targeting the CD40-CD40L axis have shown efficacy in autoimmune disorders [58], offering a precision strategy to suppress pathological immune responses while potentially mitigating irAEs. The gene discussed is CD40; the disease is autoimmune disease.